PT  - JOURNAL ARTICLE
AU  - Gupta, Rajeev
AU  - Alasdair, Vanya
AU  - Gant, Bryan Williams
AU  - Enver, Tariq
TI  - Respiratory Failure in Covid19 is associated with increased monocyte expression of complement receptor 3
AID  - 10.1101/2020.05.31.20118638
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.31.20118638
4099  - http://medrxiv.org/content/early/2020/06/02/2020.05.31.20118638.short
4100  - http://medrxiv.org/content/early/2020/06/02/2020.05.31.20118638.full
AB  - A key question in COVID-19 infection is why some previously healthy patients develop severe pulmonary failure and some ultimately die. Initial pulmonary failure does not exhibit classical features of ARDS; hypercoagulability is a common laboratory feature, and pulmonary thrombotic microangiopathy has been reported post mortem1,2,3. Biomarkers cannot robustly identify such patients pre-emptively and no specific interventions exist to mitigate clinical deterioration. Mononuclear phagocytic cells are key immune cells and bind fibrinogen through the CD11b/CD18 dimer CR3, whose activated form can initiate microthrombus formation. Accordingly, we profiled circulating monocyte CD11b/CD18 cell surface density from COVID-19 infected adults who were (i) symptomatic but breathless, (ii) requiring ventilatory support, and (iii) recovering following ICU care for hypoxia.Competing Interest StatementDr Gant reported receiving personal fees from Gilead and Bio MerieuxFunding StatementUCL Biomedical Research Centre award BRC745Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UCL Biomedical Research CentreAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is provided in the manuscript